Age-related Macular Degeneration (AMD) Therapeutics Market to Witness Huge Growth in Coming Years with Profiling Leading Companies like Novartis International AG, Bayer AG

Overview:

Age-related macular degeneration (AMD) is a condition, where central vision is lost because of thinning of the macula of the retina. The AMD is also called as macular degeneration and it is observed mostly in old age population. The age-related macular degeneration can result into permanent loss of vision in people aging 60 and above. The AMD occurs in two types, dry age-related macular degeneration (dry AMD) and wet age-related macular degeneration (wet AMD). In dry AMD the macula gets thinner with the age, which leads to central vision loss. Whereas, in wet AMD an abnormal growth of blood vessels under retina is observed. Treatment for dry AMD is not yet available, however, injections of anti-vascular endothelial growth factor (anti-VEGF) are used to manage wet AMD.

Request Here For FREE PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/786

Drivers:

Increasing aged population highly susceptible to various age-related disorders such as arthritis, diabetes, macular degeneration, and diabetes is expected to propel growth of the global market of age-related macular degeneration therapeutics during the forecast period. For instance, in 2017, as per the World Population Prospects, the global geriatric population aging over 60 years was 962 million and it is likely to increase to 2.1 billion by 2050.

Furthermore, rising cases of macular degeneration related to age are also expected to boost growth of the global age-related macular degeneration therapeutics market over the forecast period. For instance, in January 2019, the BrightFocus Foundation reported that macular degeneration affects around 11 million individuals in the U.S. the number is projected to increase by 2050 to 22 million making it a foremost cause of blindness in the U.S.

Moreover, market players are inclining towards adoption of various strategies such as mergers, acquisitions, and agreements, which is expected to drive growth of the global age-related macular degeneration therapeutics market through the forecast period. For instance, in September 2019, Boehringer Ingelheim made a co-development and license agreement with Inflammasome Therapeutics Inc. for development of three treatments for patients having retinal disease like diabetic macular edema (DME), diabetic retinopathy (DR), and age-related macular degeneration (AMD).

Get FREE Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/786

Regional Analysis:

North America is expected to witness a strong growth in the age-related macular degeneration therapeutics market due to frequent approvals and launches of novel age-related macular degeneration therapeutics products in the region. For instance, in October 2019, the U.S. FDA granted approval to Novatris for Beovu (brolucizumab) injection developed for treating age-related macular degeneration (AMD).

In august 2018, the U.S. Food and Drug Administration (FDA) approved supplement Biologics License Application (sBLA) to Regeneron Pharmaceuticals, Inc., for EYLEA injection, which is created for wet age-related macular degeneration (wet AMD) treatment.

Market Taxonomy:

The global age-related macular degeneration (AMD) therapeutics market is segmented by drug type, distribution channel, type, and geography.

By drug type:

• Aflibercept

• Ranibizumab

• Bevacizumab

• Brolucizumab

• Pegaptanib

• Others

By distribution channel:

• Hospital Pharmacies

• Online Pharmacies

• Retail Pharmacies

By type:

• Dry AMD

• Wet AMD

Do You Have Specific Requirement? Ask To Our Experts: https://www.coherentmarketinsights.com/insight/talk-to-analyst/786

By region:

• North America

• Europe

• Latin America

• Middle East

• Asia Pacific

• Africa

Key players:

Major players active in the global age-related macular degeneration therapeutics market are Bayer AG, F. Hoffmann-La Roche Ltd. Amgen Inc., Novartis International AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., and Bausch Health Companies Inc.

Reasons to Purchase this Report

• Current and future of global Age-related Macular Degeneration (AMD) Therapeutics Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations

Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/786

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Age-related Macular Degeneration (AMD) Therapeutics Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Age-related Macular Degeneration (AMD) Therapeutics Industry Impact

Chapter 2 Global Age-related Macular Degeneration (AMD) Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Age-related Macular Degeneration (AMD) Therapeutics (Volume and Value) by Type
2.3 Global Age-related Macular Degeneration (AMD) Therapeutics (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Age-related Macular Degeneration (AMD) Therapeutics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Age-related Macular Degeneration (AMD) Therapeutics Market Analysis
Chapter 6 East Asia Age-related Macular Degeneration (AMD) Therapeutics Market Analysis
Chapter 7 Europe Age-related Macular Degeneration (AMD) Therapeutics Market Analysis
Chapter 8 South Asia Age-related Macular Degeneration (AMD) Therapeutics Market Analysis
Chapter 9 Southeast Asia Age-related Macular Degeneration (AMD) Therapeutics Market Analysis
Chapter 10 Middle East Age-related Macular Degeneration (AMD) Therapeutics Market Analysis
Chapter 11 Africa Age-related Macular Degeneration (AMD) Therapeutics Market Analysis
Chapter 12 Oceania Age-related Macular Degeneration (AMD) Therapeutics Market Analysis
Chapter 13 South America Age-related Macular Degeneration (AMD) Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Age-related Macular Degeneration (AMD) Therapeutics Business
Chapter 15 Global Age-related Macular Degeneration (AMD) Therapeutics Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology